- Domiciles
- Mexico
Domicile · Latin America
Mexico.
Mexico carries the pharmaceutical manufacturing exposure of the group. Three positions were held through the Mexican company at 30 June 2026, entered between US$6 million and US$18 million: a sterile-injectable plant, a generics manufacturer and a contract manufacturer that supplies regulated markets to the north. Each depends on a plant licence and a set of export registrations that take years to obtain and can be lost in a single inspection cycle.
- People in Mexico City
- 6
- Positions held through the Mexican company
- 3 of 47
- Client portfolio attributed
- US$6 million
- Manufacturing licences on the register
- 11
- Local entity
- IGUAKO Capital México, S. de R.L. de C.V.
- Entity type
- Sociedad de responsabilidad limitada de capital variable; investment holding company
- Role
- Pharmaceutical manufacturing exposure
- City
- Mexico City
- Currency
- Mexican peso for local costs; facilities and equity are documented in US dollars
- Time zone
- Central time, six hours behind Coordinated Universal Time
- Languages
- Spanish, with English for Investment Committee papers and investor reporting
- Region
- Latin America
Presence
Six people at Level 15, Reforma Pavilion, Mexico City, under Valentina Ochoa-Brightwater, Head of Office. The office opened in 2024.
Why this domicile
- A manufacturing base that serves both a large domestic market and the regulated export markets to the north, on plant licences that are slow to grant and slower to replace.
- Sterile-injectable capacity is scarce, capital-hungry and difficult to build, which is the kind of advantage the firm underwrites as structural rather than temporary.
- A local company allows Mexican shareholdings, employment and supplier contracts to sit under Mexican law, where the plants and their regulators are.
- Proximity to the specialty-materials suppliers on which those plants depend, which the office covers as part of the same supply chain.
The regulatory-affairs researcher in the office keeps a register of every licence, registration and inspection finding on which those positions depend, and the Investment Committee reads that register before any follow-on capital is committed. Six people work in the office: three in origination, two in credit and one in regulatory-affairs research. US$6 million of the client portfolio under stewardship is attributed to Mexico, held through the same co-investment structures used in Brazil.
IGUAKO Capital México, S. de R.L. de C.V. was registered in 2024, the year the office opened, and holds the Mexican shareholdings beneath the Curaçao and Panama structures. Peso payments to suppliers and staff run through Tepeyac Payments, a licensed payments institution appointed in the same year, which returns a same-day reconciliation file to the credit team and screens each batch under the group sanctions policy.
Mexico is a manufacturing market rather than a client market, and the office is built accordingly: no client money is held, no discretionary mandate is run and no product is distributed. The 2031 Latin American phase of Programme Latitude adds a second origination team for the contract-development segment, funded from realised proceeds. Proceeds from Mexican positions are reallocated through Panama in the same way as Brazilian proceeds.
Services booked here
- Growth capital for licensed generic and sterile-injectable manufacturers.
- Structured finance for contract manufacturers supplying regulated export markets.
- Regulatory-affairs research on manufacturing licences and export registrations.
- Local holding of the Mexican positions and oversight of their shareholder agreements.
- Supply-chain coverage of specialty-materials counterparties serving those manufacturers.
Local entities
The register.
| Entity | Purpose |
|---|---|
| IGUAKO Capital México, S. de R.L. de C.V. | Investment holding company, employer of the Mexico City team, registered in 2024. |
| IGUAKO Farmacéutica México, S. de R.L. de C.V. | Holds the sterile-injectable and generics positions and their shareholder agreements. |
| Latitude Manufactura Estructurada, S.A. de C.V. | Lends to the contract manufacturer against plant equipment and export receivables. |
Regulatory approach
IGUAKO Capital México, S. de R.L. de C.V. is an investment holding company. It does not take deposits, does not manage third-party money, does not act as a broker and offers no security or investment product to the public in Mexico, and it therefore holds no authorisation from the local financial services regulator. It is registered with the national taxpayer registry, files the electronic accounting the jurisdiction requires and maintains the register of beneficial owners that the tax code obliges every Mexican company to keep and to produce on request. Foreign investment in the company is notified to the national register of foreign investment. Manufacturing, distribution and export licences are held by the portfolio companies and are supervised by the health authority that granted them. The compliance officer in Mexico City reports to the Group Financial Crime function and works to the same manual as São Paulo.
Regulatory notices
Six notices for Mexico.
Each notice combines the group standard with the provisions that apply in this jurisdiction.
Also in the region